## Yuan-Lin Guo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5821747/publications.pdf

Version: 2024-02-01

136 papers	2,563 citations	24 h-index	315739 38 g-index
137	137 docs citations	137	2804
all docs		times ranked	citing authors

#	Article	IF	CITATIONS
1	Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. Journal of Thoracic Disease, 2018, 10, 6137-6146.	1.4	122
2	Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 2014, 234, 441-445.	0.8	96
3	Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. Diabetes Care, 2019, 42, 1312-1318.	8.6	82
4	Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. Journal of Clinical Lipidology, 2014, 8, 494-500.	1.5	68
5	Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes. Hypertension, 2018, 71, 1039-1046.	2.7	68
6	Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis, 2017, 260, 67-74.	0.8	65
7	Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. Annals of Medicine, 2018, 50, 576-586.	3.8	61
8	Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 570-579.	2.4	49
9	High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. Journal of Clinical Lipidology, 2015, 9, 26-34.	1.5	48
10	Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9. Clinical Drug Investigation, 2013, 33, 877-883.	2.2	46
11	Relation of ABO blood groups to the severity of coronary atherosclerosis: An Gensini score assessment. Atherosclerosis, 2014, 237, 748-753.	0.8	46
12	Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Annals of Medicine, 2016, 48, 305-312.	3.8	44
13	Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 45.	6.8	44
14	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. Heart Lung and Circulation, 2016, 25, 975-981.	0.4	43
15	Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics With Coronary Artery Disease. American Journal of the Medical Sciences, 2017, 354, 117-124.	1.1	43
16	The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovascular Diabetology, 2020, 19, 104.	6.8	42
17	Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. International Journal of Cardiology, 2014, 174, 863-864.	1.7	39
18	Positive correlation of plasma PCSK9 levels with HbA <sub>1c</sub> in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2016, 32, 193-199.	4.0	36

#	Article	IF	CITATIONS
19	Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovascular Diabetology, 2018, 17, 48.	6.8	33
20	PCSK9 and lipid lowering drugs. Clinica Chimica Acta, 2014, 437, 66-71.	1.1	32
21	Identification of familial hypercholesterolemia in patients with myocardial infarction: A Chinese cohort study. Journal of Clinical Lipidology, 2016, 10, 1344-1352.	1.5	32
22	Higher Fibrinogen Level is Independently Linked with the Presence and Severity of New-Onset Coronary Atherosclerosis among Han Chinese Population. PLoS ONE, 2014, 9, e113460.	2.5	30
23	Plasma big endothelin-1 levels at admission and future cardiovascular outcomes: A cohort study in patients with stable coronary artery disease. International Journal of Cardiology, 2017, 230, 76-79.	1.7	29
24	Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. BMJ Open, 2017, 7, e015041.	1.9	28
25	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart, 2020, 106, 1228-1235.	2.9	28
26	Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. Journal of Translational Medicine, 2018, 16, 345.	4.4	27
27	Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatology International, 2021, 15, 413-423.	4.2	27
28	Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 167.	6.8	25
29	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. Journal of Lipid Research, 2020, 61, 1254-1262.	4.2	25
30	Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease. Cardiovascular Diabetology, 2020, 19, 36.	6.8	24
31	Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovascular Diabetology, 2020, 19, 111.	6.8	24
32	Association of Fibrinogen with Severity of Stable Coronary Artery Disease in Patients with Type 2 Diabetic Mellitus. Disease Markers, 2014, 2014, 1-8.	1,3	22
33	Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Scientific Reports, 2017, 7, 360.	3.3	22
34	Intensive genetic analysis for Chinese patients with very high triglyceride levels: Relations of mutations to triglyceride levels and acute pancreatitis. EBioMedicine, 2018, 38, 171-177.	6.1	22
35	The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis, 2018, 277, 7-14.	0.8	22
36	Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a. Journal of Translational Medicine, 2020, 18, 195.	4.4	22

#	Article	IF	CITATIONS
37	Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diabetes and Vascular Disease Research, 2015, 12, 258-264.	2.0	21
38	Enhanced proâ€protein convertase subtilisin/kexin type 9 expression by Câ€reactive protein through p38 <scp>MAPK</scp> â€ <scp>HNF</scp> 1α pathway in HepG2 cells. Journal of Cellular and Molecular Medicine, 2016, 20, 2374-2383.	3.6	21
39	Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study. Biomarkers, 2018, 23, 647-653.	1.9	20
40	Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status. Cardiovascular Diabetology, 2019, 18, 134.	6.8	20
41	Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. Journal of Translational Medicine, 2019, 17, 367.	4.4	20
42	Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Annals of Translational Medicine, 2021, 9, 1517-1517.	1.7	20
43	Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification. Annals of Clinical Biochemistry, 2018, 55, 158-164.	1.6	19
44	Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Lipids in Health and Disease, 2018, 17, 252.	3.0	19
45	Relation of Leukocytes and Its Subsets Counts with the Severity of Stable Coronary Artery Disease in Patients with Diabetic Mellitus. PLoS ONE, 2014, 9, e90663.	2.5	18
46	Relationship of Highâ€Density Lipoprotein Cholesterol With Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention in Patients With Lowâ€Density Lipoprotein Cholesterol Below 70Âmg/dL. Journal of the American Heart Association, 2015, 4, e001412.	3.7	18
47	Circulating non–HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. Journal of Clinical Lipidology, 2015, 9, 794-800.	1.5	18
48	Apoprotein C-III: A review of its clinical implications. Clinica Chimica Acta, 2016, 460, 50-54.	1.1	18
49	Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease. Nutrition and Metabolism, 2017, 14, 41.	3.0	18
50	Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A caseâ€control study. Metabolism: Clinical and Experimental, 2018, 79, 33-41.	3.4	18
51	Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids in Health and Disease, 2018, 17, 265.	3.0	18
52	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case–Control Study. Clinical and Translational Gastroenterology, 2019, 10, e00011.	2.5	18
53	Association of plasma free fatty acids levels with the presence and severity of coronary and carotid atherosclerotic plaque in patients with type 2 diabetes mellitus. BMC Endocrine Disorders, 2020, 20, 156.	2.2	18
54	ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 411-417.	2.6	17

#	Article	IF	Citations
55	Plasma <scp>d</scp> -Dimer as a Useful Marker Predicts Severity of Atherosclerotic Lesion and Short-Term Outcome in Patients With Coronary Artery Disease. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 633-640.	1.7	17
56	HDL subfractions and very early CAD: novel findings from untreated patients in a Chinese cohort. Scientific Reports, 2016, 6, 30741.	3.3	17
57	Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective cohort study.  Cardiovascular Diabetology, 2021, 20, 84.	6.8	17
58	Lipoprotein subfractions partly mediate the association between serum uric acid and coronary artery disease. Clinica Chimica Acta, 2015, 441, 109-114.	1.1	16
59	Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease. Heart Lung and Circulation, 2015, 24, 1203-1210.	0.4	16
60	Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing. Journal of Geriatric Cardiology, 2013, 10, 361-8.	0.2	16
61	Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes. Atherosclerosis, 2014, 237, 536-543.	0.8	15
62	Association of Big Endothelin-1 with Coronary Artery Calcification. PLoS ONE, 2015, 10, e0142458.	2.5	15
63	Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2018, 32, e22442.	2.1	15
64	Association between fibrinogen level and the severity of coronary stenosis in 418 male patients with myocardial infarction younger than 35 years old. Oncotarget, 2017, 8, 81361-81368.	1.8	15
65	Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study. Hepatology International, 2021, 15, 1337-1346.	4.2	15
66	Familial hypercholesterolemia in very young myocardial infarction. Scientific Reports, 2018, 8, 8861.	3.3	14
67	High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes. Hypertension Research, 2019, 42, 1783-1793.	2.7	14
68	Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima–media thickness in hypertensives. Hypertension Research, 2016, 39, 598-605.	2.7	13
69	Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart Lung and Circulation, 2019, 28, 1009-1017.	0.4	13
70	Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis, 2019, 291, 27-33.	0.8	13
71	Lipoprotein (a)-mediated vascular calcification: population-based and in vitro studies. Metabolism: Clinical and Experimental, 2022, 127, 154960.	3.4	13
72	Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-8.	1.2	12

#	Article	IF	Citations
73	Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. Journal of Clinical Lipidology, 2014, 8, 423-432.	1.5	12
74	Short- and long-term effects of Xuezhikang (è¡€è,,,康), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chinese Journal of Integrative Medicine, 2016, 22, 96-100.	1.6	12
75	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. Heart Lung and Circulation, 2017, 26, 211-218.	0.4	12
76	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thrombosis and Haemostasis, 2021, 121, 1161-1168.	3.4	12
77	Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. Liver International, 2021, 41, 1294-1304.	3.9	12
78	Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration. World Journal of Cardiology, 2010, 2, 160.	1.5	12
79	Remnant cholesterol predicts periprocedural myocardial injury following percutaneous coronary intervention in poorly-controlled type 2 diabetes. Journal of Cardiology, 2017, 70, 113-120.	1.9	11
80	Severe aortic valve stenosis in a 14-year-old boy with sitosterolemia. Journal of Clinical Lipidology, 2019, 13, 49-53.	1.5	11
81	Impact of diabetes on coronary severity and cardiovascular outcomes in patients with heterozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2021, , .	1.8	11
82	High-sensitivity C-reactive protein mediates in part the impact of ABO blood group on coronary artery disease. International Journal of Cardiology, 2014, 177, 641-643.	1.7	10
83	C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease. Annals of Medicine, 2016, 48, 83-88.	3.8	10
84	Plasma free fatty acids in relation with the severity of coronary artery disease in non-diabetics: A Gensini score assessment. IJC Metabolic & Endocrine, 2017, 14, 48-52.	0.5	10
85	Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study. BMC Cardiovascular Disorders, 2020, 20, 465.	1.7	10
86	Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study. Cardiovascular Diabetology, 2020, 19, 15.	6.8	10
87	Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. Hypertension Research, 2021, 44, 1158-1167.	2.7	10
88	Evaluation of Red Blood Cell Distribution Width in Patients with Cardiac Syndrome X. Disease Markers, 2013, 34, 333-339.	1.3	9
89	Systemic Inflammatory Markers Are Closely Associated with Atherogenic Lipoprotein Subfractions in Patients Undergoing Coronary Angiography. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	9
90	Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes. Personalized Medicine, 2018, 15, 521-529.	1.5	9

#	Article	IF	Citations
91	Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. Prostaglandins and Other Lipid Mediators, 2019, 144, 106345.	1.9	9
92	A Novel Modified System of Simplified Chinese Criteria for Familial Hypercholesterolemia (SCCFH). Molecular Diagnosis and Therapy, 2019, 23, 547-553.	3.8	9
93	Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study. Journal of Translational Medicine, 2020, 18, 373.	4.4	9
94	Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes. Cardiovascular Diabetology, 2020, 19, 152.	6.8	9
95	Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis. Current Medical Science, 2020, 40, 879-884.	1.8	9
96	Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status. Atherosclerosis, 2021, 330, 29-35.	0.8	9
97	Association of small dense LDL-cholesterol with disease severity, hypertension status and clinical outcome in patients with coronary artery disease. Journal of Hypertension, 2021, 39, 511-518.	0.5	9
98	Fibrinogen and the Severity of Coronary Atherosclerosis among Adults with and without Statin Treatment: Lipid as a mediator. Heart Lung and Circulation, 2016, 25, 558-567.	0.4	8
99	Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget, 2017, 8, 12333-12341.	1.8	8
100	Heart-type fatty acid binding protein predicts cardiovascular events in patients with stable coronary artery disease: a prospective cohort study. Annals of Translational Medicine, 2020, 8, 1349-1349.	1.7	8
101	The difference between fasting and non-fasting lipid measurements is not related to statin treatment. Annals of Translational Medicine, 2021, 9, 386-386.	1.7	8
102	Relationship of lipid and lipoprotein ratios with coronary severity in patients with new on-set coronary artery disease complicated with type 2 diabetics. Journal of Geriatric Cardiology, 2016, 13, 685-692.	0.2	8
103	Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. Cardiovascular Diabetology, 2021, 20, 214.	6.8	8
104	Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Clinica Chimica Acta, 2015, 446, 195-200.	1.1	7
105	Effect of glycemic and lipid achievements on clinical outcomes type 2 diabetic, Chinese patients with stable coronary artery disease. Journal of Diabetes and Its Complications, 2016, 30, 115-120.	2.3	7
106	High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. Atherosclerosis, 2017, 263, 104-111.	0.8	7
107	Elevated resting heart rate is associated with the severity of coronary artery disease in non-treated patients who underwent coronary angiography: potential role of lipoprotein subfractions. Archives of Physiology and Biochemistry, 2017, 123, 356-363.	2.1	7
108	Big endothelin-1 level is a useful marker for predicting the presence of isolated coronary artery ectasia. Biomarkers, 2017, 22, 331-336.	1.9	7

#	Article	IF	Citations
109	A modified algorithm with lipoprotein(a) added for diagnosis of familial hypercholesterolemia. Clinical Cardiology, 2019, 42, 988-994.	1.8	7
110	Lipoprotein(a) Is Associated with the Presence and Severity of New-Onset Coronary Artery Disease in Postmenopausal Women. Journal of Women's Health, 2020, 29, 503-510.	3.3	7
111	Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2020, 34, e23161.	2.1	7
112	Free triiodothyronine in relation to coronary severity at different ages: Gensini score assessment in 4206 euthyroid patients. Journal of Geriatric Cardiology, 2016, 13, 978-983.	0.2	7
113	Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e101719.	2.5	6
114	Free fatty acids as a marker for predicting periprocedural myocardial injury after coronary intervention. Postgraduate Medical Journal, 2019, 95, 18-22.	1.8	6
115	Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. The Lancet Regional Health - Western Pacific, 2021, 17, 100286.	2.9	6
116	Effects of Hedan Tablet (e-a,¹ç‰‡) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study. Chinese Journal of Integrative Medicine, 2016, 22, 660-665.	1.6	5
117	Distribution of ABO Blood Groups and Coronary Artery Calcium. Heart Lung and Circulation, 2017, 26, 593-598.	0.4	5
118	Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thrombosis Journal, 2021, 19, 90.	2.1	5
119	NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. Lipids in Health and Disease, 2022, 21, 3.	3.0	5
120	Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia. Journal of Translational Medicine, 2021, 19, 498.	4.4	5
121	Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans. Chronic Diseases and Translational Medicine, 2018, 4, 117-126.	1.2	4
122	Predictive value of big endothelin-1 on outcomes in patients with myocardial infarction younger than 35Âyears old. Personalized Medicine, 2018, 15, 25-33.	1.5	4
123	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. Frontiers in Cardiovascular Medicine, 2020, 7, 113.	2.4	4
124	Association of serum lipoprotein(a) level with the severity and prognosis of calcific aortic valve stenosis: a Chinese cohort study. Journal of Geriatric Cardiology, 2020, 17, 133-140.	0.2	4
125	Impact of glucose and lipid markers on the correlation of calculated and enzymatic measured lowâ€density lipoprotein cholesterol in diabetic patients with coronary artery disease. Journal of Clinical Laboratory Analysis, 2018, 32, e22399.	2.1	3
126	Thyroid function and PCSK9 in euthyroid subjects with coronary artery disease. Clinical Lipidology, 2015, 10, 235-242.	0.4	2

#	Article	IF	CITATIONS
127	ApoB is superior to LDL-C or non-HDL-C as a lipid marker for predicting the presence and severity of atherosclerosis in female patients with myocardial infarction. Hellenic Journal of Cardiology, 2017, 58, 223-225.	1.0	2
128	Atherogenic dyslipidaemia and cardiovascular events in patients with diabetes or pre-diabetes and stable coronary artery disease: a prospective, cohort study. BMJ Open, 2021, 11, e037340.	1.9	2
129	Clinical features of coronary artery ectasia in the elderly. Journal of Geriatric Cardiology, 2014, 11, 185-91.	0.2	2
130	SORBS2 as a molecular target for atherosclerosis in patients with familial hypercholesterolemia. Journal of Translational Medicine, 2022, 20, 233.	4.4	2
131	Lipid profiles in nontreated Chinese patients with stable coronary artery disease: a cross-sectional study. Clinical Lipidology, 2015, 10, 369-378.	0.4	1
132	Homozygous familiar hypercholesterolemia in China: Case series from the national lipid clinics and literature review. IJC Metabolic & Endocrine, 2017, 14, 75-80.	0.5	1
133	Differences in phenotype, genotype and cardiovascular events between patients with probable and definite heterozygous familial hypercholesterolemia. Personalized Medicine, 2019, 16, 467-478.	1.5	1
134	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2022, 9, 797297.	2.4	1
135	Visit-to-visit variability of lipid and cardiovascular events in patients with familial hypercholesterolemia. Annals of Translational Medicine, 2021, 9, 556-556.	1.7	0
136	Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. Frontiers in Endocrinology, 2022, 13, 860698.	3.5	0